Cybulla, M.; Nicholls, K.; Feriozzi, S.; Linhart, A.; Torras, J.; Vujkovac, B.; Botha, J.; Anagnostopoulou, C.; West, M.L., on behalf of the FOS Study Group.
Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease. J. Clin. Med. 2022, 11, 4810.
https://doi.org/10.3390/jcm11164810
AMA Style
Cybulla M, Nicholls K, Feriozzi S, Linhart A, Torras J, Vujkovac B, Botha J, Anagnostopoulou C, West ML on behalf of the FOS Study Group.
Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease. Journal of Clinical Medicine. 2022; 11(16):4810.
https://doi.org/10.3390/jcm11164810
Chicago/Turabian Style
Cybulla, Markus, Kathleen Nicholls, Sandro Feriozzi, Aleš Linhart, Joan Torras, Bojan Vujkovac, Jaco Botha, Christina Anagnostopoulou, and Michael L. West on behalf of the FOS Study Group.
2022. "Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease" Journal of Clinical Medicine 11, no. 16: 4810.
https://doi.org/10.3390/jcm11164810
APA Style
Cybulla, M., Nicholls, K., Feriozzi, S., Linhart, A., Torras, J., Vujkovac, B., Botha, J., Anagnostopoulou, C., & West, M. L., on behalf of the FOS Study Group.
(2022). Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease. Journal of Clinical Medicine, 11(16), 4810.
https://doi.org/10.3390/jcm11164810
